AVAH vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AVAH's Piotroski F-Score of 5/9 indicates a borderline stable financial health, but the absence of an Altman Z-Score and a dangerously high Debt/Equity ratio of 152.32 signal severe financial distress risk. Despite strong revenue growth (22.2% YoY) and impressive earnings surprises (average +362.87% in last 4 quarters), the company trades at a premium valuation (P/E 18.68, Price/Book 147.02) with no dividend and negative ROE. Insider selling totaling $7.14M in 6 months further undermines confidence, while the stock has underperformed over the past 6 months despite a 3-year gain of 506.1%. The Graham Number of $0.63 suggests deep undervaluation, but the intrinsic value of $2.59 is not supported by current fundamentals, indicating the market prices in aggressive growth expectations.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AVAH vs LLY: Head-to-Head Comparison
This page compares Aveanna Healthcare Holdings Inc. (AVAH) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.